Some reported long-term side effects of HAART are dyslipidaemia, insulin resistance/diabetes mellitus type-II and an increased risk of myocardial infarction [2-7]. An increased bleeding tendency (mainly joint,

muscle and subcutaneous bleeding, but also spontaneous intracranial bleeding) has been reported in patients with inherited bleeding disorders using protease inhibitors [8-11]. Over 25 years of follow-up is now available for haemophilia patients who were infected with HIV in the 1980s. The aim of this study was to retrospectively asses the course and complications of HIV infection, the presence of comorbidity and the effects of HAART in these patients. Data on the first 14 years of follow-up of a large proportion of our cohort were published by Roosendaal et al.

in 1998 [12]. As part of a retrospective evaluation of comorbidity Pexidartinib in a large cohort of haemophilia patients [13], data on HIV infection, its treatment and all types of comorbidity were collected of all HIV-positive haemophilia patients who were treated at the Van Creveldkliniek, a large haemophilia treatment centre in the learn more Netherlands, at any point between 1980 and 2010. Patients visit our clinic at least once a year, and their medical records have been meticulously kept since 1972, enabling reliable retrospective data collection. Follow-up ended at either last clinical evaluation before 1 September 2010, transfer to another treatment centre, or death. For patients who were still alive and treated at our centre in 2010, recent height, weight, blood pressure, HIV-RNA levels, CD4 counts Vildagliptin and cholesterol and triglyceride levels were recorded as well. The date of HIV seroconversion was estimated by calculating

the mid-point in time between the last-negative and first-positive anti-HIV ELISA tests. For patients for whom the date of seroconversion could not be calculated, the mean date of seroconversion of the total group was imputed. AIDS was diagnosed according to the 1993 European definition [14]. HAART was defined as a combination of at least three antiretroviral drugs that typically includes a protease inhibitor (PI) or a non-nucleoside-analogue reverse-transcriptase inhibitor (NNRTI) plus two nucleoside-analogue reverse-transcriptase inhibitors (NRTIs). Hypertension was defined as blood pressure over 140/90 mmHg and/or the use of antihypertensive medication. The study was approved by the Medical Ethics Review Board of the University Medical Center Utrecht. Kaplan–Meier survival analyses were performed to assess AIDS-free survival and overall survival. AIDS-free follow-up ended at the moment of diagnosis of the first AIDS-defining disease. Data were censored at the moment of death, transfer to another haemophilia treatment centre or last clinical visit before 1 September 2010.